Law and Regulations

In part 2, McMahan contextualizes the recent FTC-Caremark settlement with some of the industry’s major reform efforts in recent history.

Based on discussions from a recent webinar debate on the 340B Drug Pricing Program, we’re revealing how differently key stakeholders see a program that pharmacists participate in every day.

Tom Kraus, JD, of ASHP, and Shawn Gremminger, MPP, of the National Alliance of Healthcare Purchaser Coalitions, face off on the 340B Drug Pricing Program.

This episode explores PBMs’ copay collection discrepancies and how improper documentation can be the downfall for pharmacy business.

The major retail entity owns and operates pharmacies across many grocery stores, including Giant, Stop & Shop, Food Lion, and more.

This episode highlights the FDA’s announcement regarding GLP-1 supply stabilization and critical compliance strategies for 503A pharmacies.

As PBM-pharmacy relationships evolve in real time, staying proactive when a PBM audit comes through could be the difference between thriving and losing essential business.

Federal court blocks abrupt childhood vaccine schedule changes, raising insurance and liability uncertainty as pharmacies navigate shifting guidance and growing parent hesitancy.

Represented by Frier Levitt, multiple hospital systems filed lawsuits on May 21, 2026, targeting a variety of entities existing under CVS Health.

From supporting MTM services to reaching unhoused populations, the 340B program is a powerhouse for patient care, access, and affordability.

As debates heat up between anti-abortion and pro-life advocates, the federal government places a hold on any action toward mifepristone’s approval.

Benjamin Jolley, PharmD, presents on recent developments regarding pharmacy benefit manager reform on the state and federal levels.

This episode highlights the landmark FTC settlement with Express Scripts and what independent pharmacies and plan sponsors can expect going forward.

With a key exemption under DSCSA expiring at the end of the year, Matt Sample from Cencora helps pharmacies understand the tools and processes they need now to best comply with the law.

Matt Sample, senior vice president of manufacturer, quality, and replenishment operations at Cencora, discusses DSCSA compliance hurdles, VRS tools, and a new push toward 12-digit NDCs.

In their continued fight against major health care corporations, Senators Elizabeth Warren and Josh Hawley are aiming to delink ownership among PBMs, insurers, and wholesalers.

Anne Cassity, senior vice president of government affairs at NCPA, discusses the next moves of both PBMs and community pharmacy advocates following the signing of HR 7148.

With President Trump’s signing of HR 7148, experts are now racing to get a grasp on the monumental shifts in pharmacy that will stem from this new legislation.

As lawmakers continue to deliberate on HR 7148, pharmacy law expert, Jesse Dresser, Esq, joined Drug Topics to discuss its provisions related to PBMs.

This episode explores important insights on PBM reform and what pharmacies can look out for throughout 2026.

In part 2, ASCP’s senior policy expert James Lewis breaks down the MTF system and how it is impacting the thousands of pharmacies that dispense Medicare-covered drugs.

Focused on lowering costs and saving patients money, the plan is focused on drug prices, insurance premiums, and some of health care’s largest companies.

This December 2025 order is an extension of HHS’ recommendation to reconsider marijuana as a Schedule III medication in 2023.

During his second term, President Trump has bolstered his approach at lowering prescription drug prices in the US through innovative yet unprecedented decisions.

A conversation with NCPDP’s Rick Sage explored the lasting effects on pharmacy stemming from the record-breaking government shutdown.